Skip to content
Heart icon (animated) heart icon (static)
Explore more Johnson & Johnson sites:
A graphic of the flag of Australia alt
A graphic of the flag of Argentina alt
A graphic of the flag of Brazil alt
A graphic of the national flag of Canada alt
A graphic of the flag of Chile alt
A graphic of the national flag of the People's Republic of China alt
A graphic of the national flag of Colombia alt
A graphic of the national flag of Ecuador alt
A graphic of the flag of Germany alt
A graphic of the national flag of India alt
A graphic of the national flag of Japan alt
A graphic of the flag of Mexico alt
A graphic of the flag of Paraguay alt
A graphic of the flag of Peru alt
A graphic of the flag of Russia alt
Switzerland
A graphic of the flag of Switzerland alt
A graphic of the national flag of Uruguay alt
A graphic of the flag of Venezuela alt
Share
Download Report

Selected Pharmaceuticals in Late Stage U.S. and E.U. Development or Registration as of July 21, 2021

Pulmonary Hypertension

macitentan

Chronic thromboembolic pulmonary hypertension 75mg
Phase III US
Phase III EU

macitentan

Pulmonary arterial hypertension 75mg
Phase III US
Phase III EU

macitentan w/tadalafil FDC

Pulmonary arterial hypertension
Phase III US
Phase III EU

OPSUMIT (macitentan)

Fontan-palliated in adolescent (>12 years old) and adult patients
Phase III US
Phase III EU

OPSUMIT (macitentan)

Pediatric pulmonary arterial hypertension
Phase III US
Phase III EU

UPTRAVI (selexipag)

Pulmonary arterial hypertension IV
Filed 9/20 US

UPTRAVI (selexipag)

Chronic thromboembolic pulmonary hypertension
Phase III US
Phase III EU

UPTRAVI (selexipag)

Pediatric pulmonary arterial hypertension
Phase III US
Phase III EU
This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. (2) aprocitentan developed in collaboration with Idorsia; (3) XARELTO co-developed with Bayer HealthCare; (5) DARZALEX licensed from Genmab A/S; (6) IMBRUVICA developed in collaboration with Pharmacyclics, LLC, an AbbVie company; (7) BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; (8) Niraparib licensed from Tesaro; (9) BCMA CAR-T licensed from Legend Biotech; (10) Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S; (11) DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab , Talquetamab);
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue